ALT vs LLY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
LLY is the larger of the two ($1.26T market cap): the incumbent the market prices for continued execution (27.96x forward earnings, beta 0.39). ALT is the smaller challenger ($390.98M), priced similarly on forward earnings (-3.01x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ALT vs LLY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALT | LLY | What it tells you |
|---|---|---|---|
| Market cap | $390.98M | $1.26T | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -3.01 | 27.96 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.15 | 0.39 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 2% of range | 93% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.82 | 31.27 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ALT and LLY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALT and LLY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALT and LLY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Altimmune (ALT) do?
Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo. On the strength of IMPACT, pemvidutide received FDA Breakthrough Therapy Designation in MASH.
What does Eli Lilly (LLY) do?
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.
ALT vs LLY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ALT drivers: Differentiated GLP-1/glucagon profile; MASH opportunity.
- LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. For LLY, lLY trades at a premium valuation (about 42x trailing and 27x forward earnings, and roughly 14x sales, as of October 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply.
ALT or LLY: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALT if you believe its drivers more; LLY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALT and LLY guides.
ALT vs LLY: the full fundamentals
ALT. As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. At about $446 million the market cap now sits below the roughly $519 million of cash and investments and under book value, which means the market is assigning little or negative value to the pipeline despite Breakthrough and Fast Track designations. Nine analysts carry a mean target near $17, far above the price, and the next quarterly report is expected around November 5, 2026.
LLY. At about $1,266 a share on October 16, 2026, Eli Lilly is valued near $1.13 trillion, roughly 42x trailing earnings and 27x the roughly $47.48 in EPS analysts expect for 2027. That premium rests on revenue growth near 48% in the latest quarter and margins (about 54% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the October 29 third-quarter report (consensus about $7.16 EPS on $22.45 billion revenue) is the next data point.
Headline figures (approximate, October 2026): ALT shows product revenue None (clinical-stage), cash and investments (jun 30, 2026) ~$519 million, net loss (ttm) ~$92 million, eps (q2 2026 actual vs est.) ~-$0.12 vs ~-$0.12; LLY shows revenue (ttm) ~$79.7 billion, q2 2026 revenue ~$23.0 billion (up ~48% YoY), q2 2026 eps $8.38 vs ~$6.58 est., gross / operating margin (ttm) ~83% / ~54%.
The bottom line: ALT vs LLY
ALT and LLY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALT and LLY exposure against your real portfolio. It is not an investment adviser.
Wondering how ALT or LLY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Altimmune
Ask Walnut's AI anything about ALT and see how it fits what you own.
FAQ
What is the difference between ALT and LLY?
+
Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALT or LLY the better stock?
+
Neither is universally better. LLY is the larger incumbent; ALT is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALT or LLY?
+
On forward P/E (as of November 2026), ALT trades at -3.01x and LLY at 27.96x, so ALT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALT and LLY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALT vs LLY?
+
ALT: Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders; the April 2026 offering already did so. The share price has fallen to its 52-week low even as the trials advanced, which shows how little near-term support clinical milestones have given the stock. LLY: LLY trades at a premium valuation (about 42x trailing and 27x forward earnings, and roughly 14x sales, as of October 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. The balance sheet has also become more leveraged as Lilly funds capacity: debt was about $54.9 billion against about $9 billion of cash at June 30, 2026, and free cash flow of about $11 billion is far below operating cash flow of about $28 billion because of heavy capital spending. The third-quarter consensus implies only about 2% EPS growth year over year, so the October 29 report sets a lower bar than recent quarters.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALT or LLY; figures are approximate and dated (as of November 2026). Verify current data before investing.